Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial

Authors:

Abstract
No abstract available
Funding Information
  • AstraZeneca plc

This publication has 27 references indexed in Scilit: